Revolution Medicines : RVMD Corporate Presentation Q1 2021

Translating Frontier Oncology Targets to

Outsmart Cancer™

Corporate Overview

Q1-2021

January 12, 2021

© 2021 Revolution Medicines

Legal Disclaimer

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to maintain existing collaborations, including with Sanofi, and establish new strategic collaborations, licensing or other arrangements, the scope, progress, results and costs of developing our product candidates or any other future product candidates, the potential market size and size of the potential patient populations for our product candidates, the timing and likelihood of success of obtaining product approvals, plans and objectives of management for future operations, the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines' Quarterly Report filed with the Securities and Exchange Commission on November 12, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements or other information contained herein to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

This presentation concerns anticipated products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). It is currently limited by Federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

2

Summary

Clinical-stage precision oncology company addressing multiple, large unmet needs in RAS-addicted cancers

• Systematic, focused, science-driven strategy

RAS(ON) Inhibitors target diverse oncogenic RAS variants via highly differentiated profiles

• RMC-6291 (KRASG12C) enters development
• RMC-6236(RASMULTI) enters development

RAS Companion Inhibitors are potential backbones of targeted combinations to maximize clinical benefit

• RMC-4630(SHP2) exhibits clinical activity, advancing in broad program
• RMC-5552(mTORC1/4EBP1) prepares to enter clinic
• RMC-5845(SOS1) enters development

3

RAS(ON) Proteins Cause Cancer, RAS Addiction and Drug Resistance

1.

Multiple Receptor Tyrosine Kinases (RTKs)

Many RAS

family variants

underlie

addiction

2.

RAS(ON) form

drives oncogenic

signaling

SHP2

SOS1

RAS(OFF)

RAS(ON)

K/NRASG12C

Cell Growth, Survival,

& Cancer

3.

Natural circuits are

drug resistance

pathways, requiring companion drugs for deep and durable responses

mTORC1

RTK-driven signaling pathway Feedback loop

4